Early Phase 1 Head and Neck Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent to participate
• Adults aged 18 to 75 years old (any gender)
• People with an expected survival of at least 3 months
• People with a general health and activity level rated between 0 and 2 on a standard oncology scale (meaning able to carry out at least some daily activities)
• People who have been diagnosed with EBV-positive nasopharyngeal carcinoma (a type of throat/head cancer linked to the Epstein-Barr virus), confirmed by a specific laboratory test on tissue samples taken within the past 5 years
• People who have at least one tumour that can be measured using standard imaging criteria
• People whose nasopharyngeal carcinoma has come back or spread, and whose cancer has not responded to at least two previous rounds of treatment
• People for whom a blood collection procedure (apheresis) can be safely carried out
• People whose side effects from previous cancer treatments have largely resolved to a minimal level (below grade 1 on a standard side-effect scale)
• People of childbearing potential (male or female) who are willing to use effective contraception during the study and for 6 months after treatment ends; women of childbearing age must also have a negative pregnancy test within 72 hours before the first dose

Who may not be able to join:

• People with active cancer that has spread to the brain or central nervous system, unless it has been treated and is considered stable
• People who test positive for HIV, active Hepatitis B (with detectable virus levels above a certain threshold), or active Hepatitis C
• People with mental health or psychological conditions that would make it difficult to participate in or be assessed during the trial
• People with a serious autoimmune disease who require long-term use of immune-suppressing medications
• People who have had an active or uncontrolled infection requiring treatment throughout the body within the 14 days before joining the trial
• People with any unstable ongoing illness affecting the whole body
• People with significant problems with important organs such as the lungs, brain, or kidneys
• People who have had major surgery or a serious physical injury within 4 weeks before the cell therapy, or who are expected to need major surgery during the trial
• People who received their last dose of radiation or other anti-cancer treatment within 4 weeks before the cell therapy
• People who have had, or currently have, another cancer that was not curable within the past 3 years — with exceptions for certain early-stage or fully resolved cancers (confirm with trial site)
• People who have received CAR-T cell therapy (a type of immune cell therapy) within the past 6 months
• People who have graft-versus-host disease (a condition that can occur after certain transplant procedures)
• People who are currently on ongoing systemic steroid medication (taken by mouth or injection, not inhaled or applied to skin), or who are expected to need long-term systemic steroids during the trial; also people who received systemic steroids within 72 hours before the cell infusion
• People with a history of severe allergic reactions
• People who require blood-thinning (anticoagulant) medication
• Women who are pregnant or breastfeeding, or anyone (male or female) planning to conceive within 6 months
• People the trial investigators consider unsuitable for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.